CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BemiparinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2439 Take Control Wiki 0.71
drug1826 Placebo (for Zonisamide) Wiki 0.71
drug2723 Zonisamide Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D000437 Alcoholism NIH 0.41

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19

The 2019 coronavirus disease (Covid-19) is a new disease caused by the SARS-CoV2 virus of which many things are not yet known. Among others, there is a need to define the best therapeutic strategy to treat Covid-19, improving patients survival and reducing complications in its management, for which many different types of treatments are being tested. The drug being tested in this clinical trial is called bemiparin. Bemiparin is a drug authorized as a prevention and as a treatment for deep vein thrombosis (blood clots in one or more veins, generally in the legs) and venous thromboembolism (when the clot can detach and lodge in other organs such as the lungs). Covid-19 patients have been shown to be at increased risk of developing clotting problems such as those described above. In this context, this clinical trial is being carried out to find out if certain doses of bemiparin can contribute to better management of the disease.

NCT04420299 Covid-19 Drug: Bemiparin Drug: Bemiparin

Primary Outcomes

Description: Combined worsening variable. Presence of any of the following will be considered worseing: Death. ICU admission. Need for either non-invasive or invasive mechanical ventilation. Progression to moderate / severe respiratory distress syndrome according to objective criteria (Berlin definition). Venous thromboembolism (deep vein thrombosis or pulmonary embolism) or arterial (acute myocardial infarction or stroke).

Measure: Proportion of patients that worsen

Time: Day 10 +/- 1

Secondary Outcomes

Description: Mortality from any cause

Measure: Mortality from any cause at day 28

Time: Day 28

Description: Proportion of subjects that requires admission to the ICU

Measure: Proportion of subjects that requires admission to the ICU

Time: From study start to day 28

Description: Proportion of subjects requiring non-invasive mechanical ventilation

Measure: Proportion of subjects requiring non-invasive mechanical ventilation

Time: From study start to day 28

Description: Proportion of subjects requiring invasive mechanical ventilation.

Measure: Proportion of subjects requiring invasive mechanical ventilation.

Time: From study start to day 28

Description: Proportion of subjects with some organ failure

Measure: Proportion of subjects with some organ failure

Time: From study start to day 28

Description: Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline

Measure: Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline

Time: From study start to day 28

Description: Proportion of subjects with pathological angioTAC at day 10 +/-1

Measure: Proportion of subjects with pathological angioTAC

Time: At day 10 +/-1

Description: Proportion of subjects with improvement in chest radiography

Measure: Proportion of subjects with improvement in chest radiography

Time: At day 10 +/-1

Description: Proportion and median hospital discharge between patients in both groups.

Measure: Proportion and median hospital discharge between patients in both groups.

Time: From study start to day 28

Description: Titration score

Measure: Titration score

Time: From study start to day 28

Description: Ferritin score

Measure: Ferritin score

Time: From study start to day 28

Description: D-dimer modification score

Measure: D-dimer modification score

Time: From study start to day 28

Description: Adverse events (total and serious)

Measure: Adverse events (total and serious).

Time: From study start to day 28

Description: Related adverse events (total and serious).

Measure: Related adverse events (total and serious).

Time: From study start to day 28

Description: Clinically relevant major and non major hemorrhages.

Measure: Clinically relevant major and non major hemorrhages.

Time: From study start to day 28

2 A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19

The 2019 coronavirus disease (Covid-19) is a new disease caused by the SARS-CoV2 virus of which many things are not yet known. Among others, there is a need to define the best therapeutic strategy to treat Covid-19, improving patients survival and reducing complications in its management, for which many different types of treatments are being tested. The drug being tested in this clinical trial is called bemiparin. Bemiparin is a drug authorized as a prevention and as a treatment for deep vein thrombosis (blood clots in one or more veins, generally in the legs) and venous thromboembolism (when the clot can detach and lodge in other organs such as the lungs). Covid-19 patients have been shown to be at increased risk of developing clotting problems such as those described above. In this context, this clinical trial is being carried out to find out if certain doses of bemiparin can contribute to better management of the disease.

NCT04420299 Covid-19 Drug: Bemiparin Drug: Bemiparin

Primary Outcomes

Description: Combined worsening variable. Presence of any of the following will be considered worseing: Death. ICU admission. Need for either non-invasive or invasive mechanical ventilation. Progression to moderate / severe respiratory distress syndrome according to objective criteria (Berlin definition). Venous thromboembolism (deep vein thrombosis or pulmonary embolism) or arterial (acute myocardial infarction or stroke).

Measure: Proportion of patients that worsen

Time: Day 10 +/- 1

Secondary Outcomes

Description: Mortality from any cause

Measure: Mortality from any cause at day 28

Time: Day 28

Description: Proportion of subjects that requires admission to the ICU

Measure: Proportion of subjects that requires admission to the ICU

Time: From study start to day 28

Description: Proportion of subjects requiring non-invasive mechanical ventilation

Measure: Proportion of subjects requiring non-invasive mechanical ventilation

Time: From study start to day 28

Description: Proportion of subjects requiring invasive mechanical ventilation.

Measure: Proportion of subjects requiring invasive mechanical ventilation.

Time: From study start to day 28

Description: Proportion of subjects with some organ failure

Measure: Proportion of subjects with some organ failure

Time: From study start to day 28

Description: Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline

Measure: Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline

Time: From study start to day 28

Description: Proportion of subjects with pathological angioTAC at day 10 +/-1

Measure: Proportion of subjects with pathological angioTAC

Time: At day 10 +/-1

Description: Proportion of subjects with improvement in chest radiography

Measure: Proportion of subjects with improvement in chest radiography

Time: At day 10 +/-1

Description: Proportion and median hospital discharge between patients in both groups.

Measure: Proportion and median hospital discharge between patients in both groups.

Time: From study start to day 28

Description: Titration score

Measure: Titration score

Time: From study start to day 28

Description: Ferritin score

Measure: Ferritin score

Time: From study start to day 28

Description: D-dimer modification score

Measure: D-dimer modification score

Time: From study start to day 28

Description: Adverse events (total and serious)

Measure: Adverse events (total and serious).

Time: From study start to day 28

Description: Related adverse events (total and serious).

Measure: Related adverse events (total and serious).

Time: From study start to day 28

Description: Clinically relevant major and non major hemorrhages.

Measure: Clinically relevant major and non major hemorrhages.

Time: From study start to day 28

No related HPO nodes (Using clinical trials)